高级搜索
同时抑制VEGF、hTERT和Bcl-xl表达对喉癌细胞生长增殖的影响[J]. 肿瘤防治研究, 2009, 36(12): 991-995. DOI: 10.3971/j.issn.1000-8578.2009.12.001
引用本文: 同时抑制VEGF、hTERT和Bcl-xl表达对喉癌细胞生长增殖的影响[J]. 肿瘤防治研究, 2009, 36(12): 991-995. DOI: 10.3971/j.issn.1000-8578.2009.12.001
Effect of Simultaneously Blocking VEGF,hTERT and Bcl-xl Expression on Laryngeal Squamous Carcinoma[J]. Cancer Research on Prevention and Treatment, 2009, 36(12): 991-995. DOI: 10.3971/j.issn.1000-8578.2009.12.001
Citation: Effect of Simultaneously Blocking VEGF,hTERT and Bcl-xl Expression on Laryngeal Squamous Carcinoma[J]. Cancer Research on Prevention and Treatment, 2009, 36(12): 991-995. DOI: 10.3971/j.issn.1000-8578.2009.12.001

同时抑制VEGF、hTERT和Bcl-xl表达对喉癌细胞生长增殖的影响

Effect of Simultaneously Blocking VEGF,hTERT and Bcl-xl Expression on Laryngeal Squamous Carcinoma

  • 摘要: 目的 研究同时抑制VEGF、hTERT和Bcl-xl的表达对体内、外喉癌细胞生长增殖的影响。 方法 使用针对VEGF、hTERT和Bcl-xl mRNA的shRNA真核表达载体:pshRNA-VEGF-hTERT-Bcl-xl。通过脂质体的介导将该质粒转染至体外培养的喉鳞癌Hep-2细胞。四甲基偶氮唑蓝(MTT) 检测该质粒对Hep-2细胞的毒性作用;构建喉鳞癌荷瘤裸鼠动物模型,采用瘤体内多点注射的方式将质粒导入瘤体内,观察质粒对移植瘤的生长抑制作用。 结果 质粒pshRNA-VEGF-hTERT-Bcl-xl成功转染到喉癌细胞中并表达。经质粒pshRNA-VEGF-hTERT-Bcl-xl处理后,MTT结果显示癌细胞增殖能力显著下降,与0.9%氯化钠溶液治疗的对照组比较,在处理后24h、48h和72h,细胞增殖活性分别降至62.22%,28.77%和10.24%。pshRNA-VEGF-hTERT-Bcl-xl质粒治疗组裸鼠移植瘤生长缓慢,体积明显小于对照组,首次治疗后28天抑瘤率为90.2%,与0.9%氯化钠溶液治疗的对照组比较,P<0.01。 结论 同时抑制VEGF、hTERT、Bcl-xl表达可显著提高喉鳞癌的治疗效果。该实验为多基因靶向的肿瘤基因治疗提供了新思路。

     

    Abstract: Objective To investigate the effects of inhibition VEGF,hTERT and Bcl-xl by RNA interference on laryngeal carcinoma in vitro and in vivo. Methods A recombinant plasmid containing 3 different short hairpin RNA (shRNA) segments termed pshRNA-VEGF-hTERT-Bcl-xl was used. Cells were treated with these plasmids. Cell viability was examined by using the MTT assay. The cytotoxic effect of pshRNA-VEGF-hTERT-Bcl-xl was evaluated in the subcutaneous xenograft tumors. Results pshRNA-VEGF-hTERT-Bcl-xl exhibited a potent antitumor effect on Hep-2 cells. MTT assay confirmed cytotoxic effect. The in vivo study showed tumor volume was significantly smaller in pshRNA-VEGF-hTERT-Bcl-xl treated group than that in control group. The inhibitory rate was 90.2%. Conclusion Our study demonstrated that the application of vector-based RNAi technology involved in blocking multiple targets would be a promising therapeutic modality in the gene therapy of human laryngeal cancers.

     

/

返回文章
返回